The goals for UArizona President Robert C. Robbins, MD, include securing funding for the UArizona Health Sciences Center for Advanced Molecular and Immunological Therapies and working with Arizona State University and Northern Arizona University to expand research at the College of Medicine – Phoenix.

A blog reviewing the American Association of Pharmaceutical Scientists PharmSci 360 Meeting 2022 includes an interview with Patrick T. Ronaldson, PhD, professor of pharmacology in the College of Medicine – Tucson.

A University of Arizona College of Nursing expert is available to discuss smoking cessation research, including approaches to help people quit.

With flu cases in Arizona significantly above the state's five-year average, there is concern for people from racial and ethnic groups with lower flu vaccination rates and higher flu hospitalization rates, including Latinos, African Americans and Native Americans.

Pamela S. Smith, MD, clinical assistant professor in the College of Medicine – Phoenix, is one of three alumni to be inducted into the distinguished alumni Hall of Fame at Conrad Weiser High School.

The UArizona Health Sciences Center for Advanced Molecular and Immunological Therapies, or CAMI, received its first private philanthropic support as part of a new $10 million gift from the Steele Foundation.

A new study has linked APOE4 with faulty cholesterol processing in the brain, which in turn leads to defects in the insulating sheaths that surround nerve fibers and facilitate their electrical activity, changes that could cause memory and learning deficits.

Pediatric hospitals remain under intense pressure in Canada amid a resurgence of childhood respiratory viruses, ongoing shortages of children's pain medication and the return of the annual flu season.

Rachna Shroff, MD, MS, associate dean of clinical and translational research and associate professor in the College of Medicine – Tucson, participated in an online roundtable discussion on front-line therapy in metastatic hepatocellular carcinoma.

Identifying genetic mutations in lung cancer has allowed researchers to develop treatments that target specific biomarkers over the past 20 years, but more research is needed.